Deprecated: Return type of DrupalCacheArray::offsetExists($offset) should either be compatible with ArrayAccess::offsetExists(mixed $offset): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /home/rprlib/prod72/www/includes/bootstrap.inc on line 362
Deprecated: Return type of DrupalCacheArray::offsetGet($offset) should either be compatible with ArrayAccess::offsetGet(mixed $offset): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /home/rprlib/prod72/www/includes/bootstrap.inc on line 369
Deprecated: Return type of DrupalCacheArray::offsetSet($offset, $value) should either be compatible with ArrayAccess::offsetSet(mixed $offset, mixed $value): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /home/rprlib/prod72/www/includes/bootstrap.inc on line 381
Deprecated: Return type of DrupalCacheArray::offsetUnset($offset) should either be compatible with ArrayAccess::offsetUnset(mixed $offset): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in /home/rprlib/prod72/www/includes/bootstrap.inc on line 388 botulinum toxins, type A
https://www.rpr.lib.ok.us/taxonomy/term/774/all
enNonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update
https://www.rpr.lib.ok.us/resource/nonsurgical-treatments-urinary-incontinence-women-systematic-review-update
<div class="field field-name-field-artifact-uploaded-date field-type-datetime field-label-inline clearfix">
<div class="field-label">Date Added: </div>
<div class="field-items">
<div class="field-item even"><span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2018-10-22T00:00:00-05:00">October 22, 2018</span></div>
</div>
</div>
<div class="field field-name-field-artifact-journal field-type-text field-label-inline clearfix">
<div class="field-label">Journal/Publication: </div>
<div class="field-items">
<div class="field-item even">Comparative Effectiveness Review</div>
</div>
</div>
<div class="field field-name-field-artifact-publisher field-type-text field-label-inline clearfix">
<div class="field-label">Publisher: </div>
<div class="field-items">
<div class="field-item even">Agency for Healthcare Research and Quality</div>
</div>
</div>
<div class="field field-name-field-artifact-published-date field-type-datetime field-label-inline clearfix">
<div class="field-label">Publication Date: </div>
<div class="field-items">
<div class="field-item even"><span class="date-display-single" property="dc:date" datatype="xsd:dateTime" content="2018-08-08T00:00:00-05:00">August 8, 2018</span></div>
</div>
</div>
<div class="field field-name-field-artifact-issue field-type-text field-label-inline clearfix">
<div class="field-label">Issue: </div>
<div class="field-items">
<div class="field-item even">212</div>
</div>
</div>
<div class="field field-name-field-artifact-url field-type-link-field field-label-inline clearfix">
<div class="field-label">URL: </div>
<div class="field-items">
<div class="field-item even"><a href="https://effectivehealthcare.ahrq.gov/topics/urinary-incontinence-update/final-report-2018" target="_blank">Nonsurgical Treatments for Urinary Incontinence in Women: A Systematic Review Update</a></div>
</div>
</div>
<div class="field field-name-field-artifact-type field-type-taxonomy-term-reference field-label-inline clearfix">
<div class="field-label">Type: </div>
<div class="field-items">
<div class="field-item even">Meta-analyses, Reviews, and Guidelines</div>
</div>
</div>
<div class="field field-name-field-artifact-doi-1 field-type-text field-label-inline clearfix">
<div class="field-label">DOI (1): </div>
<div class="field-items">
<div class="field-item even">10.23970/AHRQEPCCER212</div>
</div>
</div>
<div class="field field-name-field-artifact-keywords field-type-taxonomy-term-reference field-label-above">
<div class="field-label">Keywords </div>
<div class="field-items">
<div class="field-item even"><a href="/tags/urinary-tract-infections" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">urinary tract infections</a></div>
<div class="field-item odd"><a href="/tags/behavior-therapy" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">behavior therapy</a></div>
<div class="field-item even"><a href="/tags/urinary-incontinence" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">urinary incontinence</a></div>
</div>
</div>
<div class="field field-name-field-artifact-mesh field-type-taxonomy-term-reference field-label-above">
<div class="field-label">MeSH </div>
<div class="field-items">
<div class="field-item even"><a href="/mesh/urinary-incontinence" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">urinary incontinence</a></div>
<div class="field-item odd"><a href="/mesh/behavior-therapy" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">behavior therapy</a></div>
<div class="field-item even"><a href="/mesh/botulinum-toxins-type" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">botulinum toxins, type A</a></div>
<div class="field-item odd"><a href="/mesh/urinary-tract-infections" typeof="skos:Concept" property="rdfs:label skos:prefLabel" datatype="">urinary tract infections</a></div>
</div>
</div>
<div class="field field-name-field-artifact-editor-note field-type-text-long field-label-hidden">
<div class="field-items">
<div class="field-item even"><p>This is a concise summary of the evidence regarding management of stress and urge-type urinary incontinence in women.</p>
<p> </p>
<p> </p>
<p> </p>
</div>
</div>
</div>
<div class="field field-name-field-artifact-text-availability field-type-list-text field-label-hidden">
<div class="field-items">
<div class="field-item even">Free full text</div>
</div>
</div>
<div class="field field-name-field-artifact-document-content field-type-entityreference field-label-hidden">
<div class="field-items">
<div class="field-item even"><div class="view view-artifact-docs view-id-artifact_docs view-display-id-block view-dom-id-dff11aa9b16ae38553d454cd08dfcddf">
<div class="view-content">
<div class="views-row views-row-1 views-row-odd views-row-first views-row-last">
</div>
</div>
</div></div>
</div>
</div>
<div class="field field-name-body field-type-text-with-summary field-label-hidden">
<div class="field-items">
<div class="field-item even" property="content:encoded"><p><strong>Introduction.</strong> About 17 percent of adult women have had urinary incontinence (UI), classified as stress, urgency, or mixed. Stress UI is associated with an inability to retain urine with activities that increase intraabdominal pressure. Urgency UI is associated with the sudden, compelling urge to void. Mixed UI occurs when both are present.</p>
<p><strong>Methods.</strong> We updated the Agency for Healthcare Research and Quality's 2012 systematic review with new literature searches in MEDLINE®, the Cochrane Central Trials Registry, the Cochrane Database of Systematic Reviews, and Embase® from 2011 through December 4, 2017. We included UI outcomes (cure, improvement, satisfaction), quality of life, and adverse events. For UI outcomes, we conducted network meta-analyses, combining direct and indirect comparisons across studies. Quality of life and adverse event outcomes are narratively described.</p>
<p><strong>Results.</strong> We identified 233 eligible studies, of which 140 reported on UI outcomes, 96 on quality of life, and 127 on adverse events. Studies evaluated 16 categories of interventions with 53 specific interventions. Fourteen intervention categories have been evaluated for UI outcomes; all except hormones and periurethral bulking agents were more effective to achieve at least one favorable UI outcome than no treatment (variable strength of evidence [SoE]). Among 1st or 2nd line interventions for stress UI, behavioral therapy (BT, alone and in combination with hormones) was more effective than either alpha agonists or hormones to achieve cure or improvement (moderate SoE); alpha agonists were more effective than hormones to achieve improvement (moderate SoE). Among treatments used as 1st or 2nd line interventions for urgency UI, BT was significantly more effective than anticholinergics to achieve cure or improvement (high SoE). Among 3rd line interventions for stress UI, intravesical pressure release, but not periurethral bulking agents, was more effective than no treatment (variable SoE). Neuromodulation, which is commonly used for treatment of urgency UI, is more effective than no treatment of stress UI for cure, improvement, and satisfaction (high SoE). Among studies of women with only stress UI, indirect evidence suggests that intravesical pressure release is more effective to achieve improvement than combination BT and neuromodulation, and triple combination neuromodulation, hormones, and BT may be more effective than either periurethral bulking or combination neuromodulation and BT (all low SoE). Among treatments used as 3rd line interventions for urgency UI, both neuromodulation and onabotulinum toxin A (BTX) are more effective than no treatment (high SoE), and BTX may be more effective than neuromodulation to achieve cure (low SoE). BT, neuromodulation, and anticholinergics resulted in better quality of life than no treatment (low SoE). Urinary tract infections (UTIs) were reported in 11 percent of women receiving transcutaneous electrical nerve stimulation and erosion in 1.6 percent of women with the periurethral bulking agent macroplastique (low SoE). Dry mouth was the most commonly reported adverse event for the anticholinergic oxybutynin (36%) and the alpha agonist duloxetine (13%) (high SoE). BTX was associated with UTIs (36%) and urinary retention (10% to 20%) (moderate SoE). Constitutional adverse events (e.g., nausea, insomnia, fatigue) were common with duloxetine (moderate SoE).</p>
<p><strong>Conclusions.</strong> Network meta-analyses demonstrated that most nonpharmacological and pharmacological interventions are more likely than no treatment to improve UI outcomes and quality of life. BT, alone or in combination with other interventions, is generally more effective than 2nd line (pharmacological) therapies alone for both stress and urgency UI. Common adverse events with pharmacological treatments include dry mouth, nausea, and fatigue. BTX is associated with urinary infections and retention. Periurethral bulking agents are associated with erosion and need for surgical removal. Large gaps remain in the literature regarding head-to-head comparisons of individual interventions.</p>
</div>
</div>
</div>
<div class="field field-name-field-resource-author field-type-taxonomy-term-reference field-label-inline clearfix">
<div class="field-label">Author/s: </div>
<div class="field-items">
<div class="field-item even">Balk, Ethan, Adam, Gaelen P., Kimmel, Hannah, Rofeberg, Valerie, Saeed, Iman, Jeppson, Peter, Trikalinos, Thomas</div>
</div>
</div>
Mon, 22 Oct 2018 16:08:25 +0000Jeffrey Wilson155 at https://www.rpr.lib.ok.us